Marc Larkins
@Johnson & Johnson
Latest period2024 - Q3ReportedManaged Assets$427.326MTotal holdings20
Assets growth rate6.66%Assets growth rate (2-Q avg)-42.13%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Johnson & Johnson's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 20 positions.
Assets under management
The assets under management (AUM) of Johnson & Johnson over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 427.326M in assets, with a quarterly growth rate of 6.66% and a 2-quarter average growth rate of -42.13%. The portfolio is managed by Marc Larkins, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
FATEFate Therapeutics, Inc.
| 2.77% | $11.827M 3.379M shares@ $3.5 avg price | |
ARWRArrowhead Pharmaceuticals, Inc.
| 1.13% | $4.796M 247,598 shares@ $19.37 avg price | |
RLYBRallybio Corporation
| 1% | $4.255M 3.636M shares@ $1.18 avg price | |
NNOXNano-x Imaging Ltd.
| 0.23% | $965,820 158,852 shares@ $6.08 avg price | |
VORVor Biopharma, Inc.
| 0.18% | $752,261 1.075M shares@ $0.71 avg price | |
LABStandard Biotools Inc
| 0.15% | $602,096 311,967 shares@ $1.93 avg price | |
ACETAdicet Bio, Inc.
| 0.13% | $524,840 364,472 shares@ $1.45 avg price | |
PHGEBiomx Inc.
| 0.05% | $196,167 192,321 shares@ $1.02 avg price | Decreased -89.99% |
CLSDClearside Biomedical, Inc.
| 0.03% | $104,751 82,481 shares@ $1.28 avg price | New Position |
SENSSenseonics Holdings, Inc.
| 0.01% | $19,101 54,621 shares@ $0.35 avg price |